Skip to main content

Table 1 Demographic and baseline characteristics

From: Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

Demographic data   
Variable   Total
   N=32
Age (years)   31-72 (58.0)
Number of regimens of previous chemotherapy   1-4 (2)
Sex Male 20 (62%)
  Female 12 (38%)
ECOG performance status 0 8 (25%)
  1 20 (63%)
  2 4 (13%)
Site of primary cancer Breast 1 (3%)
  Colon 6 (19%)
  Lung 1 (3%)
  Pancreas 2 (6%)
  Pleura 1 (3%)
  Rectum 7 (22%)
  Soft tissue 2 (6%)
  Stomach 4 (13%)
  Other 8 (25%)
  1. Continuous data: Minimum-Maximum (Median).